Introduction
Benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate, affects over 50% of men aged 60 and older, causing urinary symptoms like frequent urination, weak stream, and nocturia. Therapies range from medications to surgical interventions, each offering symptom relief but carrying potential side effects. Understanding these side effects is crucial for informed decision-making, as they can impact quality of life. This article explores common enlarged prostate therapies and their associated risks, drawing from clinical evidence.
Pharmacological Treatments
Medications are often the first-line therapy for BPH. Alpha-blockers, such as tamsulosin (Flomax) and doxazosin, relax prostate and bladder neck muscles to improve urine flow. Common side effects include dizziness (up to 15% of users), orthostatic hypotension, and retrograde ejaculation (affecting 8-18% of men), where semen enters the bladder instead of exiting. These drugs act quickly but do not shrink the prostate.
5-alpha reductase inhibitors like finasteride (Proscar) and dutasteride (Avodart) reduce prostate size by blocking dihydrotestosterone production. They take 3-6 months for benefits but cause sexual dysfunction in 5-15% of patients, including decreased libido, erectile dysfunction, and ejaculatory disorders. Long-term use has been linked to gynecomastia (breast enlargement) in 1-2% and a slight increase in high-grade prostate cancer risk per the Prostate Cancer Prevention Trial.
Combination therapy, approved by the FDA, merges both classes for better efficacy in larger prostates, yet side effects are additive, with up to 25% of men reporting sexual issues.
Minimally Invasive Procedures
For moderate symptoms unresponsive to drugs, procedures like transurethral microwave thermotherapy (TUMT) and transurethral needle ablation (TUNA) use heat to destroy prostate tissue. TUMT side effects include urinary retention (10-20%), hematuria, and dysuria lasting weeks. TUNA similarly causes temporary incontinence (5%) and ejaculatory dysfunction. These outpatient options avoid general anesthesia but may require catheterization post-procedure.
Water vapor thermal therapy (Rezum) injects steam to shrink tissue, with side effects like painful urination (30-40%) and blood in urine, usually resolving in 1-4 weeks. UroLift, a mechanical implant system, lifts prostate lobes; it preserves ejaculation in 90% of cases but risks transient urinary symptoms and device migration (rare).
Surgical Interventions
Transurethral resection of the prostate (TURP), the gold standard surgery, removes obstructing tissue. It relieves symptoms in 80-90% of patients but causes retrograde ejaculation in 65-80%, incontinence in 1-2%, and urethral stricture in 5%. Bleeding requiring transfusion occurs in 2-5%.
Laser therapies like photoselective vaporization (PVP) or holmium laser enucleation (HoLEP) minimize bleeding, with HoLEP showing durable results. Side effects mirror TURP but with lower rates: retrograde ejaculation (70%), temporary incontinence (5%). Open prostatectomy for very large glands carries higher risks of infection and recovery time.
Conclusion
While enlarged prostate therapies effectively alleviate symptoms, side effects vary by treatment modality—from sexual dysfunction with medications to ejaculatory changes post-surgery. Patient factors like prostate size, symptom severity, and comorbidities guide selection. Recent studies, including MTOPS and CombAT trials, underscore balancing efficacy against risks. Men should consult urologists for personalized plans, considering alternatives like watchful waiting for mild cases. Ongoing research into novel therapies promises fewer side effects, enhancing management of this prevalent condition.